Gossamer Bio falls after experimental lung condition drug fails in trial

Gossamer Bio

23/02/2026 14:06

** Shares of drug developer Gossamer Bio GOSS.O fall 67% to 69 cents premarket

** Co says its experimental drug, seralutinib, for a type of lung condition failed to meet the main goal in a late-stage study

** Co says patients on seralutinib improved their median walking distance by 28.2 meters, compared to 13.5 meters for those on placebo, at 24 weeks

** Adds, the results, however, did not meet the prespecified statistical threshold

** The company was testing the drug in patients with pulmonary arterial hypertension, a condition in which high blood pressure in lung arteries causes them to narrow and stiffen

** GOSS shares had risen over 242% in 2025

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))